ENDPOINTS NEWS20m
As­traZeneca, Dai­ichi Sankyo re­place lung can­cer fil­ing for En­her­tu suc­ces­sor
AstraZeneca and Daiichi Sankyo withdrew their filing for datopotamab deruxtecan (Dato-DXd) in nonsquamous non-small cell lung ...
Finanznachrichten1h
AstraZeneca PLC: Dato-DXd new BLA submitted, NSQ BLA withdrawn
Datopotamab deruxtecan (Dato-DXd) Datopotamab deruxtecan (Dato-DXd ... TNBC and HR-positive, HER2-low or negative breast cancer. The programme includes seven Phase III trials in lung cancer and five ...
STAT2h
AstraZeneca, Daiichi Sankyo change strategy on closely watched cancer drug
LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...
Daily5d
CDSCO panel Approves AstraZeneca's Protocol Amendment proposal for Datopotamab Deruxtecan study
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...
The Globe and Mail7d
HR+ HER2-ve Breast Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers
Dato-DXd: Daiichi Sankyo, Inc. Datopotamab deruxtecan (Dato-DXd) is an investigational currently in Phase III for HR-positive ...
Daiichi Sankyo's World-Leading Antibody Drug Conjugate Platform Continues to Make Progress
Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...
Business Wire12d
Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...
Cure Today15d
Phase 3 Trial Begins in mRNA-Based Therapy Plus Keytruda in Non-Small Cell Lung Cancer
The INTerpath-009 trial will investigate an individualized neoantigen therapy plus Keytruda in patients with non-small cell lung cancer post-surgery whose disease didn't fully respond to prior ...
Targeted Oncology20d
Bispecific Antibodies and ADCs Deliver a Futuristic Horizon Across Lung Cancer Settings
Recent advancements in protein engineering, especially antibody-drug conjugates, show promise in lung cancer treatment, with ivonescimab outperforming pembrolizumab in PD-L1-positive advanced ...
Targeted Oncology22d
I-SPY2.2: A Personalized Approach to Neoadjuvant Breast Cancer Treatment
Targeted Oncology: Could you summarize some of the previous research on Dato-DXd in breast cancer? Shatsky: Dato-DXd was examined in breast cancer in the TROPION-Breast trials, which showed promising ...
Cure Today24d
Resistance Mechanisms May Steer Therapy Sequences in EGFR-Mutated Lung Cancer
The study underscores the importance of understanding drug resistance to enhance therapeutic efficacy in EGFR-mutated non-small cell lung cancer. An expert discussed how the understanding of ...
precisionmedicineonline25d
FDA Approves Astellas' Vyloy, Chemo in First-Line CLDN18.2-Positive Gastric Cancer With Roche CDx
The agency concurrently approved Roche's Ventana CLDN18 (43-14A) RxDx Assay as a companion diagnostic for identifying gastric cancer patients whose tumors express CLDN18.2. The agency approved Vyloy ...